Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation and Depletion (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Depreciation and Depletion data on record, last reported at $12206.0 in Q2 2025.

  • For Q2 2025, Depreciation and Depletion rose 124.37% year-over-year to $12206.0; the TTM value through Jun 2025 reached $50204.0, up 5.16%, while the annual FY2025 figure was $50204.0, 5.16% up from the prior year.
  • Depreciation and Depletion reached $12206.0 in Q2 2025 per INM's latest filing, roughly flat from $12203.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $14242.0 in Q4 2023 and bottomed at $4217.0 in Q3 2021.
  • Average Depreciation and Depletion over 5 years is $10249.0, with a median of $11394.5 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: tumbled 57.88% in 2024, then soared 124.37% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $6246.0 in 2021, then rose by 28.98% to $8056.0 in 2022, then surged by 76.79% to $14242.0 in 2023, then decreased by 14.27% to $12209.0 in 2024, then decreased by 0.02% to $12206.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $12206.0 in Q2 2025, $12203.0 in Q1 2025, and $12209.0 in Q4 2024.